Repligen Earnings Preview and Market Outlook | Business and Finance News

Repligen’s Q2 earnings drop Tuesday with strong momentum—last quarter smashed expectations with 194.3M in revenue, up 14.8% YoY—and analysts still back them despite a slight growth slowdown to ~10.7% this quarter. Peers like Medpace and West Pharma show mixed stock reactions, while the sector averages a 1.3% gain. Repligen’s stock dipped 3.6% recently, trading below its $178.05 average analyst target, but its track record of hitting targets keeps the outlook bullish. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/ee1e1c9cab0aa0cc